Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Passage Bio stock | $27.72

Own Passage Bio stock in just a few minutes.

Fact checked

Passage Bio, Inc is a biotechnology business based in the US. Passage Bio shares (PASG) are listed on the NASDAQ and all prices are listed in US Dollars. Passage Bio employs 20 staff and has a market cap (total outstanding shares value) of USD$1.3 billion.

How to buy shares in Passage Bio

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Passage Bio. Find the stock by name or ticker symbol: PASG. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Passage Bio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$27.72, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Passage Bio, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Passage Bio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Passage Bio share price

Use our graph to track the performance of PASG stocks over time.

Passage Bio shares at a glance

Information last updated 2020-12-09.
Latest market closeUSD$27.72
52-week rangeUSD$8.09 - USD$38.23
50-day moving average USD$18.3926
200-day moving average USD$19.2579
Wall St. target priceUSD$28.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Passage Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Bonds
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Passage Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Passage Bio price performance over time

Historical closes compared with the close of $27.72 from 2020-12-09

1 week (2021-01-11) N/A
1 month (2020-12-22) 4.80%
3 months (2020-10-18) N/A
6 months (2020-07-18) N/A
1 year (2020-01-18) N/A
2 years (2019-01-18) N/A
3 years (2018-01-18) N/A
5 years (2016-01-18) N/A

Passage Bio financials

Gross profit TTM USD$0
Return on assets TTM -19.96%
Return on equity TTM -32.9%
Profit margin 0%
Book value N/A
Market capitalisation USD$1.3 billion

TTM: trailing 12 months

Shorting Passage Bio shares

There are currently 1.4 million Passage Bio shares held short by investors – that's known as Passage Bio's "short interest". This figure is 5.7% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Passage Bio shares can be evaluated.

Passage Bio's "short interest ratio" (SIR)

Passage Bio's "short interest ratio" (SIR) is the quantity of Passage Bio shares currently shorted divided by the average quantity of Passage Bio shares traded daily (recently around 160583.29519451). Passage Bio's SIR currently stands at 8.74. In other words for every 100,000 Passage Bio shares traded daily on the market, roughly 8740 shares are currently held short.

However Passage Bio's short interest can also be evaluated against the total number of Passage Bio shares, or, against the total number of tradable Passage Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Passage Bio's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Passage Bio shares in existence, roughly 30 shares are currently held short) or 0.0507% of the tradable shares (for every 100,000 tradable Passage Bio shares, roughly 51 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Passage Bio.

Find out more about how you can short Passage Bio stock.

Passage Bio share dividends

We're not expecting Passage Bio to pay a dividend over the next 12 months.

Passage Bio overview

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site